Can You Take Mounjaro If You Have Crohn's Disease? (October 2026)

01 · The core answer

Can you take Mounjaro with Crohn's disease?

Mounjaro (tirzepatide) is licensed for weight management in adults and for type 2 diabetes; Crohn's disease is not a licensed use.¹

The central issue is the way the medicine works. Tirzepatide activates two natural gut-hormone receptors, and together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ A medicine that acts on the gut is a different proposition when your gut is already affected by long-term inflammation. That does not make it unsuitable for everyone with Crohn's. It means your history has to be looked at properly first.

Many people with Crohn's disease are in remission for long periods, and their weight-management needs are real. Others have active inflammation, narrowed segments of bowel, fistulas or previous surgery. These are very different situations, and a sensible prescriber will treat them differently. If you are in a flare, or your symptoms have recently changed, the honest position is to speak to your gastroenterology team before considering any new treatment.

02 · Your decision

What your prescriber will weigh up

Your prescriber needs a full picture, not a tick-box. These are the areas that usually matter most in a conversation about Crohn's disease and weight-loss treatment:

• Current disease activity: whether you are in remission, recovering from a flare or still being stabilised.
• Where the disease sits: small bowel, colon or both, and whether any narrowing has been identified on imaging.
• Past complications and surgery: any obstruction, resection, stoma or fistula.
• Your current medicines: including any immune-modifying treatment your IBD team has prescribed.
• Nutrition and absorption: weight loss is not always the goal if you have struggled to keep weight or nutrients up.
• Your reason for treatment: your weight, your related health conditions and what you hope to achieve.

Be specific in the consultation. If you tell us about a stricture, a recent hospital admission or a change in your IBD medication, the prescriber can make a safe decision. Leaving it out helps nobody. You can start with our free consultation on the Mounjaro pen page. A GPhC-registered prescriber reviews every consultation, and unsuitable orders are refunded automatically.

03 · What to do next

What to do next

Talk to your gastroenterologist or IBD nurse first, then bring their view into your prescriber consultation. Ask them directly whether a medicine that slows stomach emptying is appropriate given your bowel anatomy and current treatment. If they have concerns, you will have saved yourself a difficult start. If they are comfortable, your prescriber can build that into a cautious plan.

If you want a wider look at weight-management options with this condition, our guide to weight loss injections and Crohn's covers the injectable options, and our longer complete UK guide to Crohn's and Mounjaro goes deeper. For the wider picture of what we offer, see our weight loss clinic.

04 · How Mounjaro works

How Mounjaro works and why the gut matters

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly.¹ It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹ That appetite effect is the reason people take it. The slower stomach emptying that goes with it is the reason people with bowel conditions are asked extra questions.

It helps to separate what the medicine is designed to do from what your condition does. Mounjaro is not an anti-inflammatory and is not a treatment for Crohn's disease. It does not replace anything your IBD team has prescribed. It is a weight-management medicine, used alongside a reduced-calorie diet and increased physical activity, and it should only ever be added to your care in agreement with the clinicians who know your gut.

05 · Strictures and slow emptying

Narrowing, past surgery and slower stomach emptying

Because tirzepatide slows how quickly the stomach empties, anyone with a history of bowel narrowing or obstruction should raise it before treatment.¹ Crohn's disease can cause strictures, which are narrowed sections of bowel, and it can lead to surgery. Your prescriber will want to know if either applies to you.

Read the cautions and side effects in the patient information leaflet with your IBD team.¹³ What matters in practice is that you know your own anatomy, or can ask your gastroenterologist to explain it, before you decide.

Useful questions to take to your IBD team include whether your last imaging showed any narrowing, whether you have ever had a blockage, whether your surgery changed how food moves through you, and whether they would want to be told if you started a new medicine. Write the answers down and share them in your consultation.

06 · Flares and side effects

Telling a flare from a side effect

One practical challenge is that digestive symptoms can have more than one cause, so you and your clinicians need a clear baseline. If you start a new medicine and your bowel habit changes, it can be hard to know whether you are seeing the medicine, a flare, something you ate or an infection. The most common side effects, affecting more than 1 in 10 people, are nausea, diarrhoea, vomiting, constipation and abdominal discomfort, and they are most likely when starting treatment or moving up a dose.

A few habits make the picture clearer. Keep a simple symptom diary from before you start. Note the date of each injection and any change in your IBD medication. Agree in advance with your IBD team what would make you phone them, such as blood in the stool or persistent vomiting. If you cannot keep fluids down, contact your clinical team — dehydration needs medical help straight away. For severe or worsening abdominal pain, get medical help straight away. Do not wait to see whether it settles if something feels wrong.

You can also report any suspected side effect through the MHRA Yellow Card scheme, which helps regulators monitor medicines in real-world use.¹⁹ Our team offers side-effect support and ongoing monthly reviews, and dose changes are made by the prescribing team rather than left to guesswork. Repeat orders re-check suitability, and nothing ships automatically.

07 · Coeliac and diverticular disease

Coeliac, diverticular and other autoimmune conditions

The same principle applies to other conditions people ask about: none of them is a licensed use of Mounjaro, and each needs an individual review. The licence covers weight management in adults and type 2 diabetes, and the product information is the place to check cautions.¹

Coeliac disease is managed through a strict gluten-free diet, and nutrition is a real consideration. If you have coeliac disease, tell your prescriber how well controlled it is and whether a dietitian is involved. A medicine that reduces appetite means you must still eat enough varied, safe food.

Diverticular disease affects the wall of the large bowel. If you have had diverticulitis, a hospital admission or surgery, share that history. Because tirzepatide acts on the digestive system, your prescriber will want to understand how settled your bowel currently is.

Other autoimmune conditions vary enormously. Some, such as lupus or thyroid conditions, have little to do with the gut, and we have separate guides on lupus and Mounjaro and Graves' disease and Mounjaro. Others affect the digestive tract directly. In every case, the honest answer is that your whole history and your current medicines decide it, not the label of the condition. Kidney health also matters in this context, so see our kidney disease guide if that applies to you.

08 · Evidence and what it means

What the weight-loss evidence does and does not tell you

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

Those figures describe a general trial population. They do not tell you how someone with Crohn's disease would respond. Trial averages do not predict your own result, and your own bowel history is a separate question from average weight loss.

The sensible reading is that tirzepatide is an effective licensed weight-management medicine, and that whether it is right for you is decided by your health profile. Weight is also not the only goal for people with inflammatory bowel disease, where maintaining nutrition and strength can matter just as much. Your IBD team can help you decide what a healthy target looks like for you.

09 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

10 · Alternatives and NHS access

Alternatives and NHS access

If your prescriber or IBD team decides Mounjaro is not right for you, there are other routes, and they are worth discussing rather than giving up on weight management. These include dietitian-led support, structured activity that suits your energy levels, and other licensed medicines where appropriate. Our existing guide to orlistat and Crohn's disease support covers one alternative, and figures for it vary, so your prescriber can advise. You can also read about this class of injectable medicine and Crohn's.

On the NHS: Mounjaro is available on the NHS, but access is being phased in over several years.⁴⁶ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Your GP or IBD team is the right place to ask where you sit.

If you choose private treatment, you are still under clinical oversight. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Mounjaro is supplied through official LillyDirect supply, as genuine KwikPens, and ongoing monthly reviews are included.